Unknown

Dataset Information

0

The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.


ABSTRACT: Promoter methylation of O(6)-methylguanine-DNA methyltransferase (MGMT) is an important predictive biomarker in glioblastoma. The T variant of the MGMT promoter-enhancer single nucleotide polymorphism (SNP; rs16906252) has been associated with the presence of MGMT promoter methylation in other cancers. We examined the association of the T allele of rs16906252 with glioblastoma development, tumor MGMT methylation, MGMT protein expression, and survival outcomes.Two independent temozolomide-treated glioblastoma cohorts-one Australian (Australian Genomics and Clinical Outcomes of Glioma, n = 163) and the other American (University of California Los Angeles/Kaiser Permanente Los Angeles, n = 159)-were studied. Allelic bisulphite sequencing was used to determine if methylation was specific to the T allele. Additionally, we compared the incidence of the T allele between glioblastoma cases and matched controls to assess whether it was a risk factor for developing MGMT methylated glioblastoma.Carriage of the T allele of the rs16906252 SNP was associated with both MGMT methylation and low MGMT protein expression and predicted significantly longer survival in temozolomide-treated patients with both MGMT methylated and nonmethylated glioblastoma. Methylation was linked to the T allele, inferring that the T variant plays a key role in the acquisition of MGMT methylation. Carriage of the T allele was associated with a significantly elevated risk of developing glioblastoma (adjusted odds ratio, 1.96; P = .013), increasing further when glioblastoma was classified by the presence of MGMT methylation (adjusted odds ratio, 2.86; P = .001).The T allele of the rs16906252 SNP is a key determinant in the acquisition of MGMT methylation in glioblastoma. Temozolomide-treated patients with the rs16906252 T genotype have better survival, irrespective of tumor methylation status.

SUBMITTER: Rapkins RW 

PROVIDER: S-EPMC4633927 | biostudies-other | 2015 Dec

REPOSITORIES: biostudies-other

altmetric image

Publications

The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.

Rapkins Robert W RW   Wang Fan F   Nguyen HuyTram N HN   Cloughesy Timothy F TF   Lai Albert A   Ha Wendy W   Nowak Anna K AK   Hitchins Megan P MP   McDonald Kerrie L KL  

Neuro-oncology 20150424 12


<h4>Background</h4>Promoter methylation of O(6)-methylguanine-DNA methyltransferase (MGMT) is an important predictive biomarker in glioblastoma. The T variant of the MGMT promoter-enhancer single nucleotide polymorphism (SNP; rs16906252) has been associated with the presence of MGMT promoter methylation in other cancers. We examined the association of the T allele of rs16906252 with glioblastoma development, tumor MGMT methylation, MGMT protein expression, and survival outcomes.<h4>Methods</h4>T  ...[more]

Similar Datasets

| S-EPMC2790867 | biostudies-literature
| S-EPMC7595088 | biostudies-literature
| S-EPMC3792931 | biostudies-literature
| S-EPMC6888814 | biostudies-literature
| S-EPMC7877176 | biostudies-literature
| S-EPMC3890309 | biostudies-literature
| S-EPMC5817966 | biostudies-literature
| S-EPMC6783410 | biostudies-literature
| S-EPMC2713697 | biostudies-literature
| S-EPMC7142016 | biostudies-literature